
Bioorganic and Medicinal Chemistry Letters p. 7107 - 7112 (2011)
Update date:2022-08-02
Topics:
Chowdhury, Sarwat
Sessions, E. Hampton
Pocas, Jennifer R.
Grant, Wayne
Schr?ter, Thomas
Lin, Li
Ruiz, Claudia
Cameron, Michael D.
Schürer, Stephan
Lograsso, Philip
Bannister, Thomas D.
Feng, Yangbo
Rho kinase (ROCK) inhibitors are potential therapeutic agents to treat disorders such as hypertension, multiple sclerosis, cancers, and glaucoma. Here, we disclose the synthesis, optimization, biological evaluation of potent indole and 7-azaindole based ROCK inhibitors that have high potency on ROCK (IC 50 = 1 nM) with 740-fold selectivity over PKA (47). Moreover, 47 showed very good DMPK properties making it a good candidate for further development. Finally, docking studies with a homology model of ROCK-II were performed to rationalize the binding mode of these compounds and showed the compounds bound in both orientations to take advantage to H-bonds with Lys-121 of ROCK-II.
View Morezhejiang huangyan wanfeng pharm chem co.ltd
Contact:+86-576- 84160728
Address:No. 5 Dazha Road, Economic,Development Zone(JiangKou), Zhejiang, China
Nanjing Capatue Chemical Co., Ltd
Contact:+86-25-86371192 +86-025-85720158
Address:No.20 Jiangjun Avenue, Jiangning Economic & Technical Development Zone
Contact:+86-0512-69209969
Address:Room 317,Lushan Road,Suzhou New District,Jiangsu Province,China.
Hangzhou Donglou Bio-nutrient Co., Ltd.
Contact:+86-571-82225795,13967112289
Address:Louta Town, Xiaoshan,Hangzhou,Zhejiang
Shandong Xingshun New Material Co., Ltd.
website:http://www.sd-xingshun.com
Contact:+86-519-86461196
Address:Middle of Luhua East Road, Dingtao District
Doi:10.1021/acs.orglett.9b02462
(2019)Doi:10.1007/BF00962395
(1990)Doi:10.1016/j.bmc.2011.03.005
(2011)Doi:10.1002/cbic.201600474
(2016)Doi:10.1016/j.tet.2013.01.070
(2013)Doi:10.1016/S0040-4039(00)98815-4
(1990)